Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.75 |
| ▸ | ATP1A1 | P05023 | 8/20 | 0.67 |
| ▸ | ATP1B1 | P05026 | 8/20 | 0.67 |
| ▸ | ATP1A3 | P13637 | 8/20 | 0.67 |
| ▸ | ATP1B2 | P14415 | 8/20 | 0.67 |
| ▸ | ATP1A2 | P50993 | 8/20 | 0.67 |
| ▸ | ATP1B3 | P54709 | 8/20 | 0.67 |
| ▸ | FXYD2 | P54710 | 8/20 | 0.67 |
| ▸ | ATP1A4 | Q13733 | 8/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.66 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HBB | P68871 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14648704 | 1.00 | SMN1; SMN2 (0.75) | SMN1; SMN2ATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL12557116 | 1.00 | SMN1; SMN2 (0.75) | SMN1; SMN2ATP1A1ATP1B1ATP1A3ATP1B2 | |
| Thevetin B SCHEMBL29389027 | 0.92 | ATP1A1 (0.80) | SMN1; SMN2ATP1A1ATP1B1ATP1A3ATP1B2 | |
| Thevetin B SCHEMBL869661 | 0.92 | ATP1A1 (0.80) | SMN1; SMN2ATP1A1ATP1B1ATP1A3ATP1B2 | |
| Thevetin B SCHEMBL12556692 | 0.92 | ATP1A1 (0.80) | SMN1; SMN2ATP1A1ATP1B1ATP1A3ATP1B2 | |
| Thevetin B SCHEMBL29463277 | 0.92 | ATP1A1 (0.80) | SMN1; SMN2ATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL12556695 | 0.92 | SMN1; SMN2 (0.75) | SMN1; SMN2ATP1A1ATP1B1ATP1A3ATP1B2 | |
| Boivinide B SCHEMBL17305089 | 0.88 | HIF1A (0.72) | SMN1; SMN2ATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL29413165 | 0.88 | ATP1A1 (0.79) | SMN1; SMN2ATP1A1ATP1B1ATP1A3ATP1B2 | |
| Boivinide D SCHEMBL12557510 | 0.88 | RELA (0.76) | SMN1; SMN2ATP1A1ATP1B1ATP1A3ATP1B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10149858-B2 | Treatment for migraine | QUARTEY KINGSLEY YIANOMAH (CA) | 2018-12-11 | — | — | US | claimed |
| US-20160143936-A1 | Treatment for Migraine | QUARTEY KINGSLEY YIANOMAH (CA) | 2016-05-26 | — | — | US | claimed |
| US-8791079-B2 | Methods for treating heart failure by inhibiting the mitochondrial sodium-calcium exchanger (mNCE) | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-29 | — | — | US | claimed |
| US-20140051652-A1 | Treatment for Migraine Headache | QUARTEY KINGSLEY YIANOMAH (CA) | 2014-02-20 | — | — | US | claimed |
| US-20130244960-A1 | Treatment for Alzheimer's Disease | QUARTEY KINGSLEY YIANOMAH (CA) | 2013-09-19 | — | — | US | claimed |
| US-8394434-B2 | SCF extract containing cardiac glycoside | PHOENIX BIOTECHNOLOGY, INC. (US) | 2013-03-12 | — | — | US | claimed |
| US-20120219620-A1 | SCF Extract Containing Cardiac Glycoside | PHOENIX BIOTECHNOLOGY, INC. (US) | 2012-08-30 | — | — | US | claimed |
| US-8187644-B2 | Mixing powdered oleander leaf with supercritical carbon dioxide above critical pressure and critical temperature; depressurization and cooling to give a separated extract mixture; recovering cardiac glycoside-containing extract which acts as an antiproliferative agent; solvent extraction | PHOENIX BIOTECHNOLOGY INC. (US) | 2012-05-29 | — | — | US | claimed |
| US-20120077763-A1 | METHODS FOR TREATING HEART FAILURE BY INHIBITING THE MITOCHONDRIAL SODIUM-CALCIUM EXCHANGER (mNCE) | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-29 | — | — | US | claimed |
| WO-2010104998-A2 | METHODS FOR TREATING HEART FAILURE BY INHIBITING THE MITOCHONDRIAL SODIUM-CALCIUM EXCHANGER (MNCE) | JOHNS HOPKINS UNIVERSITY (US) | 2010-09-16 | — | — | WO | claimed |
| US-20080200401-A1 | SCF Extract Containing Cardiac Glycoside | PHOENIX BIOTECHNOLOGY, INC. (US) | 2008-08-21 | — | — | US | claimed |
| US-20060205679-A1 | Topical and oral formulations of cardiac glycosides for treating skin diseases | AZAYA THERAPEUTICS, INC. | 2006-09-14 | — | — | US | claimed |
| US-20050026849-A1 | Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases | TRINITY LABORATORIES, INC. | 2005-02-03 | — | — | US | claimed |
| WO-2004087121-A2 | WATER SOLUBLE FORMULATIONS OF DIGITALIS GLYCOSIDES FOR TREATING CELL-PROLIFERATIVE AND OTHER DISEASES | AZAYA THERAPEUTICS, INC. (US) | 2004-10-14 | — | — | WO | claimed |
| US-20040082521-A1 | Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases | Azaya Therapeutics Inc. | 2004-04-29 | — | — | US | claimed |
| US-12351819-B2 | Method for removing undifferentiated pluripotent stem cells | ACADEMIA SINICA (TW) | 2025-07-08 | — | — | US | disclosed |
| US-11083748-B2 | Zeolite molecular sieves for the removal of toxins | FRAMEWORK THERAPEUTICS, LLC (US) | 2021-08-10 | — | — | US | disclosed |
| US-20050026849-A1 | Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases | TRINITY LABORATORIES, INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2004087121-A2 | WATER SOLUBLE FORMULATIONS OF DIGITALIS GLYCOSIDES FOR TREATING CELL-PROLIFERATIVE AND OTHER DISEASES | AZAYA THERAPEUTICS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-0442744-A2 | Treatment of viral disease by glycosides | TSUMURA & CO. (JP) | 1991-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205679-A1 | Topical and oral formulations of cardiac glycosides for treating skin diseases | DSG1, PDIA5, NISCH | SMN1; SMN2 2869/4885ATP1A1 2112/4885ATP1B1 1353/4885 |
| US-20120077763-A1 | METHODS FOR TREATING HEART FAILURE BY INHIBITING THE MITOCHONDRIAL SODIUM-CALCIUM EXCHANGER (mNCE) | SLC8B1, ATP2A1, ATP2A2 | SMN1; SMN2 1088/4885ATP1A1 109/4885ATP1B1 166/4885 |
| US-20040082521-A1 | Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases | DIAPH1, CDC42, CANX | SMN1; SMN2 3323/4885ATP1A1 1419/4885ATP1B1 943/4885 |
| US-12351819-B2 | Method for removing undifferentiated pluripotent stem cells | ALPG, UGGT1, GYPA | SMN1; SMN2 3232/4885ATP1A1 212/4885ATP1B1 88/4885 |
| US-20050026849-A1 | Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases | NISCH, CANX, DSC1 | SMN1; SMN2 2401/4885ATP1A1 2061/4885ATP1B1 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.